Do Not Initiate Ohtuvayre During Acute COPD Exacerbations
Ohtuvayre (nebulized glycopyrrolate/ensifentrine) should not be started during an acute COPD exacerbation—it is a maintenance therapy for stable disease only. The FDA label explicitly states that Ohtuvayre "is not meant to relieve acute symptoms of COPD" 1, and established guidelines consistently recommend short-acting bronchodilators as the initial treatment for acute exacerbations 2.
Why This Matters for Acute Management
During a COPD exacerbation, the priority is rapid symptom relief and stabilization. The GOLD 2017 guidelines are unequivocal: short-acting inhaled β2-agonists (like albuterol), with or without short-acting anticholinergics (like ipratropium), are the recommended initial bronchodilators for acute exacerbations 2. These agents provide immediate bronchodilation, which is what patients need when experiencing acute worsening of dyspnea, cough, and sputum production.
Ohtuvayre is a long-acting maintenance medication designed for twice-daily use in stable COPD patients. Its role is to prevent exacerbations and maintain lung function over time, not to rescue patients from acute respiratory distress 1.
The Correct Acute Exacerbation Algorithm
When managing an acute COPD exacerbation, follow this evidence-based sequence:
Immediate bronchodilation:
- Start with nebulized short-acting β2-agonists (albuterol 2.5-5 mg or terbutaline 5-10 mg) 3
- Add short-acting anticholinergics (ipratropium 0.25-0.5 mg) for moderate-to-severe exacerbations or poor response to β2-agonists alone 3, 4
- Administer every 4-6 hours or more frequently if needed 3
Systemic corticosteroids:
- Prescribe oral prednisone 40 mg daily for 5 days to improve lung function, oxygenation, and shorten recovery time 2, 5
- This reduces clinical failure and hospitalization duration 5
Antibiotics when indicated:
- Use when there is increased sputum purulence, increased sputum volume, and increased dyspnea 2
- Duration should be 5-7 days 2
When to Initiate Long-Acting Bronchodilators
The guidelines are clear about timing: "Maintenance therapy with long-acting bronchodilators should be initiated as soon as possible before hospital discharge" 2. This means you wait until the patient is stabilizing and recovering from the acute event—not during the acute phase itself.
The transition typically occurs after 24-48 hours of nebulized short-acting bronchodilators, once the patient is clinically improving 3. At that point, you can switch from short-acting agents to maintenance inhalers or nebulized long-acting therapies like Ohtuvayre.
Emerging Evidence on Nebulized Glycopyrrolate in Hospitalized Patients
While recent Indian real-world studies suggest that nebulized glycopyrrolate (a different formulation than Ohtuvayre) may be used during hospitalization for exacerbations 6, 7, these represent expert opinions and retrospective observations rather than controlled trials. The experts in these studies reported initiating glycopyrrolate after initial stabilization with short-acting agents, not as first-line acute therapy 6. This aligns with the guideline principle of starting maintenance therapy once the acute phase is controlled.
Importantly, older research on glycopyrrolate combined with albuterol showed benefit in acute exacerbations 8, but this involved short-acting glycopyrrolate as an adjunct to short-acting β2-agonists—not as monotherapy and not as a long-acting maintenance agent like Ohtuvayre.
Critical Pitfalls to Avoid
Do not confuse maintenance therapy with rescue therapy. Ohtuvayre's FDA label explicitly instructs patients to "treat acute symptoms with an inhaled, short-acting beta2-agonist such as albuterol" and warns that "extra doses should not be used" for acute symptom relief 1. Starting Ohtuvayre during an exacerbation delays appropriate acute treatment and provides no immediate bronchodilation benefit.
Do not delay short-acting bronchodilators. Every minute counts during an acute exacerbation. The evidence consistently shows that short-acting agents are the cornerstone of acute management 2, 4, 5. Using a long-acting maintenance drug instead wastes precious time.
The Bottom Line
Start Ohtuvayre only after the acute exacerbation has been controlled with appropriate short-acting bronchodilators and systemic corticosteroids. Use the hospitalization or acute event as an opportunity to optimize long-term maintenance therapy before discharge, which is when Ohtuvayre becomes appropriate 2. During the acute phase, stick with proven rapid-acting therapies that have decades of evidence supporting their use in exacerbations.